Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alvaro Lopez-Sanchez has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Hélène Charlotte Bertrand

    Laboratoire Chimie Physique et Chimie du Vivant CPCV, Département de Chimie, Ecole Normale Supérieure, PSL University, Sorbonne Université, CNRS, 24 rue Lhomond75005 Paris, France

    4 shared publications
  • Giorgia Pastorin

    Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore 117544, Singapore; Integrative Sciences and Engineering Programme, NUS Graduate School, National University of Singapore, Singapore 119077, Singapore

    3 shared publications
  • Carole Nicco

    Department 3I “Infection, Immunité Et Inflammation”, Institut Cochin, INSERM U1016, Paris, France

    2 shared publications
  • Clotilde Policar

    Laboratoire Chimie Physique et Chimie du Vivant—CPCV UMR8228 Département de Chimie, Ecole Normale Supérieure PSL University, Sorbonne Université, CNRS Paris 75005 France

    2 shared publications
  • Frédéric Batteux

    Département 3I Infection, Immunité et Inflammation , Institut Cochin, INSERM U1016, Université de Paris, Paris, France

    2 shared publications
  • Giulia Adriani

    Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore

    2 shared publications

Latest Publications

  • Open Access

    Is platinum the new gold? Re-evaluating platinum's enduring role and future potential in the era of novel ovarian cancer therapies

    by Andres Pachon Roa, Ram Pravin Kumar Muthuramalingam, Alvaro Lopez-Sanchez, Lih-Wen Deng, Dan Gibson, Helene C. Bertrand, Giulia Adriani, Wee Han Ang, Giorgia Pastorin


  • Development of platinum(IV) conjugates of oxaliplatin and redox modulators as anticancer agents with reduced neurotoxicity

    by Alvaro Lopez Sanchez

    Développement de conjugués de platine(IV) d'oxaliplatine et de régulateurs redox en tant qu'agents anticancéreux à neurotoxicité réduite: La neuropathie périphérique induite par l'oxaliplatine (NPIO) est le principal effet secondaire limitant l'utilisation clinique de l'oxaliplatine (Ox), un agent chimiothérapeutique de première ligne à base de Pt(II) utilisé pour le traitement du cancer colorectal métastatique. Cette condition découle du mode d'action complexe de l'Ox et de son incapacité à discriminer entre les cellules saines et cancéreuses, entraînant son accumulation dans le système nerveux périphérique et la génération subséquente de dommages à l'ADN, de dysfonctionnement mitochondrial et de stress oxydatif, parmi d'autres effets. Ce dernier a été rapporté comme étant particulièrement impliqué dans la NPIO, et plusieurs antioxydants ont déjà été évalués dans des essais précliniques et cliniques.Ce manuscrit se concentre sur l'utilisation de mimes de la superoxyde dismutase (SOD) à base de Mn(II) de faible poids moléculaire en tant que modulateurs redox, soit en combinaison équimolaire avec l'Ox, soit liés de manière covalente au centre Pt dans une stratégie de pro-drogue de Pt(IV), pour la mitigation et la prévention de la NPIO. La synthèse, la caractérisation physicochimique, la stabilité et les évaluations de l'activité biologique seront discutées pour plusieurs formulations de pro-drogue de Pt(IV) et traitements de type combinaison avec des mimes de la SOD. Ces évaluations seront réalisées à l'aide de modèles cellulaires en monocouche et en trois dimensions de cancer colorectal, ainsi que sur divers modèles murins in vivo, où l'activité anticancéreuse et la neuroprotection, évaluée par des tests comportementaux et par des techniques moléculaires et analytiques supplémentaires, seront étudiées afin de mieux comprendre les rôles de la bioaccumulation et la régulation redox dans la NPIO. Les résultats obtenus soutiennent l'utilisation et l'investigation des mimétiques de la SOD et des complexes de Pt(IV) en tant que candidats potentiels pour contourner cet effet secondaire, actuellement dépourvu d'options thérapeutiques ou préventives.

  • NMR spectroscopy stability studies of Ru-IM, a prodrug candidate for triple negative breast cancer

    by Marayke Mayrata, Alvaro Lopez-Sanchez, Esteban P. Urriolabeitia, Sophie McCarrick, Aaron Manu, Javier E. López-Hernández, Michelle C. Neary, Maria Contel


  • Decoding the mechanism for cytotoxicity in thiolato-bridged triosmium carbonyl clusters: from serum reactivity to cellular impact

    by Xin Liang, Hélène C. Bertrand, Nicolas Delsuc, Bohong Huang, Weng Kee Leong, Alvaro Lopez-Sanchez

    Mechanism of action (MoA) studies on the cytotoxic thiolato-bridged triosmium carbonyl clusters Os3(CO)10(μ-H)(μ-SR) (2) indicates that their cytotoxicity is associated with increased reactive oxygen species (ROS) generation, G2/M cell cycle arrest, and subsequent apoptosis. Cellular uptake is a key factor, with an increased reactivity of the cluster with serum leading to reduced available concentrations in the medium thereby diminishing its anti-proliferative effect. Reactivity studies reveal that biomolecular interactions occur predominantly at the triosmium core, with a preference for amine-containing species.


  • Open Access

    Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs

    by Jia Xuan Kee, Jia Ning Nicolette Yau, Ram Pravin Kumar Muthuramalingam, Xinyi Wang, Wei Heng Chng, Alvaro Lopez-Sanchez, Kevin Kuang Wei Tay, Lih-Wen Deng, Dan Gibson, Helene C. Bertrand, et al.

    Colorectal cancer (CRC) remains a significant global health challenge, ranking third in incidence and second in mortality among cancers worldwide. This review addresses the complex landscape of CRC, focusing on incidence, mortality trends, preventive strategies, and the evolving therapeutic approaches, particularly highlighting the role of platinum-based drugs like oxaliplatin (OXP). It also underscores the increasing burden of CRC, with factors such as westernized diets, aging populations, and genetic predispositions contributing to its prevalence. Therapeutically, early detection greatly enhances survival rates, emphasizing the importance of regular colonoscopies and stool tests. For advanced CRC, chemotherapy remains pivotal, with OXP as a cornerstone treatment despite its associated chemotherapy-induced peripheral neurotoxicity (CIPN). The review explores innovative strategies to overcome challenges related to chemotherapy, such as drug resistance and side effects, highlighting recent developments in the field, such as Pt(IV) prodrugs and immunotherapeutic approaches to enhance efficacy while minimizing toxicity. Additionally, this manuscript examines experimental models for drug screening, emphasizing the role of murine models and advanced 3D in vitro systems in CRC research. Overall, the review advocates for a comprehensive approach, integrating prevention, early detection, and personalized treatments to alleviate the global burden of CRC.


  • Open Access

    A Targeted Redox‐Active Dual‐Action Pt(IV)‐Mn(II) Prodrug Displays Enhanced In Vivo Anticancer Activity

    by Alvaro Lopez‐Sanchez, Henri Chédotal, Ram Pravin Kumar Muthuramalingam, Marine Thomas, Jia Ning Nicolette Yau, Priya Ranjan Sahoo, Clotilde Policar, Frédéric Batteux, Kadda Medjoubi, Andrea Somogyi, et al.

    As FDA‐approved platinum (Pt) anticancer drugs (e.g. cisplatin, oxaliplatin and carboplatin) grapple with clinical challenges including chemoresistance and systemic side‐effects, Pt(IV) prodrugs have emerged as potent alternative chemotherapies. In this work, a novel bimetallic dual‐action Pt(IV) prodrug bearing a manganese (Mn) superoxide dismutase mimic (SODm) is presented, demonstrating high stability in solution. The prodrug displays intrinsic antisuperoxide properties and in vitro comparable cytotoxic activities to that of oxaliplatin in 2‐ and 3D colorectal cancer cellular models, as well as an increase in intracellular reactive oxygen species (ROS) production. The prodrug is further evaluated in an in vivo mice model for colorectal cancer, demonstrating a similar performance to that of oxaliplatin. Additionally, a total tumor remission is reached with a PEGylated micellar encapsulation of the prodrug. This novel formulation increases the lifetime of the prodrug and therefore its tumoral uptake and plasma content with respect to the unencapsulated drug. This enhanced activity suggests the therapeutic potential of said formulation.


  • Pt(iv) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?

    by Alvaro Lopez-Sanchez, Helene C. Bertrand

    Oxaliplatin(iv) prodrugs, classified by the role of their axial ligands, are presented with a focus on their in vitro stability and activity in in vivo models, illustrating their potential to address current Pt-based chemotherapy's main limitations.


  • Open Access

    A New Manganese Superoxide Dismutase Mimetic Improves Oxaliplatin-Induced Neuropathy and Global Tolerance in Mice

    by Caroline Prieux-Klotz, Henri Chédotal, Martha Zoumpoulaki, Sandrine Chouzenoux, Charlotte Chêne, Alvaro Lopez-Sanchez, Marine Thomas, Priya Ranjan Sahoo, Clotilde Policar, Frédéric Batteux, et al.

    Reactive oxygen species (ROS) are produced by every aerobic cell during mitochondrial oxidative metabolism as well as in cellular response to xenobiotics, cytokines, and bacterial invasion. Superoxide Dismutases (SOD) are antioxidant proteins that convert superoxide anions (O2•−) to hydrogen peroxide (H2O2) and dioxygen. Using the differential in the level of oxidative stress between normal and cancer cells, SOD mimetics can show an antitumoral effect and prevent oxaliplatin-induced peripheral neuropathy. New Pt(IV) conjugate prodrugs (OxPt-x-Mn1C1A (x = 1, 1-OH, 2)), combining oxaliplatin and a Mn SOD mimic (MnSODm Mn1C1A) with a covalent link, were designed. Their stability in buffer and in the presence of sodium ascorbate was studied. In vitro, their antitumoral activity was assessed by the viability and ROS production of tumor cell lines (CT16, HCT 116, KC) and fibroblasts (primary culture and NIH 3T3). In vivo, a murine model of colorectal cancer was created with subcutaneous injection of CT26 cells in Balb/c mice. Tumor size and volume were measured weekly in four groups: vehicle, oxaliplatin, and oxaliplatin associated with MnSODm Mn1C1A and the bis-conjugate OxPt-2-Mn1C1A. Oxaliplatin-induced peripheral neuropathy (OIPN) was assessed using a Von Frey test reflecting chronic hypoalgesia. Tolerance to treatment was assessed with a clinical score including four items: weight loss, weariness, alopecia, and diarrhea. In vitro, Mn1C1A associated with oxaliplatin and Pt(IV) conjugates treatment induced significantly higher production of H2O2 in all cell lines and showed a significant improvement of the antitumoral efficacy compared to oxaliplatin alone. In vivo, the association of Mn1C1A to oxaliplatin did not decrease its antitumoral activity, while OxPt-2-Mn1C1A had lower antitumoral activity than oxaliplatin alone. Mn1C1A associated with oxaliplatin significantly decreased OIPN and also improved global clinical tolerance of oxaliplatin. A neuroprotective effect was observed, associated with a significantly improved tolerance to oxaliplatin without impairing its antitumoral activity.